中国肝癌介入治疗的历史。
The history of interventional therapy for liver cancer in China.
作者信息
Zuo Mengxuan, Huang Jinhua
机构信息
Department of Minimally Invasive Intervention, Sun Yat-sen University Cancer Center, State Key Laboratory Of Oncology In South China, Guangzhou 510060, Guangdong, China.
出版信息
J Interv Med. 2019 Apr 30;1(2):70-76. doi: 10.19779/j.cnki.2096-3602.2018.02.02. eCollection 2018 May.
In China interventional therapy of liver cancer started in the 1980s. It is well-known that Professor Lin Gui is the founding father of Interventional radiology. Under the leadership of Lin Gui and other professors, interventional therapy of liver cancer has swiftly progressed in China. Indeed, TAI, TAE, TACE and ablation therapy have witnessed great innovations in hardware facilities, technical means, and therapeutic philosophy, while incorporating Chinese characteristics. As with the development of combined interventional therapy in China, interventional treatment of liver cancer has gradually started the process of precision and individualization. Actually, multidisciplinary, multimodal, and polymorphic treatments will be the most suitable pattern for liver cancer in the future, among which combination of interventional therapy with targeted, immunological treatments and information technology (IT) tools may bring a revolutionary breakthrough in liver cancer treatment.
中国肝癌介入治疗始于20世纪80年代。众所周知，林贵教授是介入放射学的奠基人。在林贵等教授的带领下，中国肝癌介入治疗迅速发展。事实上，经动脉灌注化疗（TAI）、经动脉栓塞化疗（TAE）、经动脉化疗栓塞（TACE）和消融治疗在硬件设施、技术手段和治疗理念方面都有了很大创新，同时融入了中国特色。随着中国联合介入治疗的发展，肝癌介入治疗已逐渐开启精准化和个体化进程。实际上，多学科、多模式、多形态治疗将是未来肝癌最适宜的模式，其中介入治疗与靶向、免疫治疗及信息技术（IT）工具的联合应用可能会给肝癌治疗带来革命性突破。
Zotero 插件